Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Share

.2022 Jun;42(2):127-134.
doi: 10.1002/npr2.12234. Epub 2022 Feb 6.

Evaluation of a natural S-equol supplement in treating premenstrual symptoms and the effect of the gut microbiota: An open-label pilot study

Affiliations

Evaluation of a natural S-equol supplement in treating premenstrual symptoms and the effect of the gut microbiota: An open-label pilot study

Takashi Takeda et al. Neuropsychopharmacol Rep.2022 Jun.

Abstract

Aim: Premenstrual syndrome causes disturbances in many women's daily activities. Isoflavones might cause changes in the estrogen cycle by their selective estrogen receptor modulator-like activities. Equol, which is a metabolite of a soy isoflavone, has greater biological activity than other soy isoflavones. In this preliminary study, we aimed to examine the effect of a natural S-equol supplement (SE5-OH) on premenstrual symptoms. The gut microbiota has recently been suggested to play an important role in brain function in psychiatric disease, such as depression. Therefore, we further aimed to evaluate the relationship of the effect of SE5-OH and the gut microbiota at preintervention.

Methods: Twenty women who showed premenstrual symptoms and were nonequol producers were enrolled in an open-label, single-arm, clinical study in which they received oral SE5-OH for two period cycles. The Daily Record of Severity of Problems (DRSP) total score was evaluated during the intervention cycles. Before taking SE5-OH, fecal samples were obtained and subjected to terminal restriction fragment length polymorphism analysis.

Results: The response rate to treatment (≥50% reduction from baseline in the DRSP total score) was 10.5%. Post hoc analysis showed a significant improvement in the change in the DRSP total score (P = .008) and DRSP scores for four core premenstrual dysphoric disorder symptoms. Multiple regression analysis showed that the percentage improvement of the DRSP total score was positively related to Bifidobacterium and negatively related to Clostridium cluster IV.

Conclusion: SE5-OH supplementation may be an acceptable treatment for premenstrual symptoms. The intestinal microbiota may have an effect on SE5-OH.

Keywords: dietary supplement; gut microbiota; isoflavone; premenstrual syndrome; women's health.

© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.

PubMed Disclaimer

Conflict of interest statement

TT received lecture fees from Otsuka Pharmaceutical Co., Ltd., which is the manufacturer of SE5‐OH. Otsuka Pharmaceutical Co., Ltd. had no role in the study conception, study planning, data analysis, or data interpretation.

Figures

FIGURE 1
FIGURE 1
Study flow chart
FIGURE 2
FIGURE 2
Schedule of enrolment, interventions, and assessments. CGI‐I, Clinical Global Impression–Improvement; DRSP, Daily Record of Severity of Problems; I‐1, first intervention cycle; I‐2, second intervention cycle; Q‐1, qualification cycle; SE5‐OH, natural S‐equol supplement
FIGURE 3
FIGURE 3
Changes in the DRSP total score before and after treatment with a natural. DRSP, Daily Record of Severity of Problems; I‐2, second intervention cycle; Q‐1, qualification cycle; S‐equol supplement
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008;371(9619):1200–10. - PMC - PubMed
    1. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;218(1):68–74. - PubMed
    1. Hofmeister S, Bodden S. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2016;94(3):236–40. - PubMed
    1. Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand. 2001;104(2):110–6. - PubMed
    1. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin‐reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356(9236):1131–6. - PubMed

Publication types

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp